4.3 Review

Genetics, Genomics, and Precision Medicine in End-Stage Kidney Disease

Journal

SEMINARS IN NEPHROLOGY
Volume 38, Issue 4, Pages 317-324

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.semnephrol.2018.05.002

Keywords

APOL1; apoliprotein L1; cardiovascular disease; diabetic nephropathy; dialysis survival

Funding

  1. Intramural Research Programs of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health
  2. Center for Cancer Research, National Cancer Institute, National Institutes of Health
  3. federal funds from the National Cancer Institute, National Institutes of Health [HHSN26120080001E]
  4. National Institutes of Health

Ask authors/readers for more resources

Recent advances in genetics of renal disease have deepened our understanding of progressive kidney disease. Here, we review genetic variants that are of particular importance to progressive glomerular disease that result in end-stage kidney disease (ESKD). Some of the most striking findings relate to APOL1 genetic variants, seen exclusively in individuals of sub-Saharan African descent, that create a predisposition to particular renal disorders, including focal segmental glomerulosclerosis and arterionephrosclerosis. We also review the genetics of cardiovascular disease in ESKD and note that little work has been published on the genetics of other ESKD complications, including anemia, bone disease, and infections. Deeper understanding of the genetics of ESKD and its complications may lead to new therapies that are tailored to an individual patient's genetic profile or are discovered based on genetic approaches that identify novel pathways of renal cell injury and repair. Published by Elsevier Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available